Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Guo-Ling Zhang *Shaanxi Key Laboratory of Phytochemistry, AIE Research Center, College of Chemistry and Chemical Engineering, Baoji University of Arts and Sciences, Baoji, China.
Da-Yong Hou *NHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, Harbin Medical University Cancer Hospital, Harbin, China. houdayong@hrbmu.edu.cn.ORCID http://orcid.org/0000-0002-7567-8663
Yixuan Chen *Guangdong Basic Research Center of Excellence for Aggregate Science, School of Science and Engineering, Shenzhen Institute of Aggregate Science and Technology, The Chinese University of Hong Kong, Shenzhen (CUHK-Shenzhen), Shenzhen, China.
Pu ChenShaanxi Key Laboratory of Phytochemistry, AIE Research Center, College of Chemistry and Chemical Engineering, Baoji University of Arts and Sciences, Baoji, China.
Jiong-Cheng WuNHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, Harbin Medical University Cancer Hospital, Harbin, China.
Yue-Ze WangNHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, Harbin Medical University Cancer Hospital, Harbin, China.ORCID http://orcid.org/0009-0007-5029-806X
Wanhai XuNHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, Harbin Medical University Cancer Hospital, Harbin, China.ORCID http://orcid.org/0000-0003-3442-7988
Zheng ZhaoGuangdong Basic Research Center of Excellence for Aggregate Science, School of Science and Engineering, Shenzhen Institute of Aggregate Science and Technology, The Chinese University of Hong Kong, Shenzhen (CUHK-Shenzhen), Shenzhen, China. zhaozheng@cuhk.edu.cn.ORCID http://orcid.org/0000-0002-5536-0439
Ben Zhong TangGuangdong Basic Research Center of Excellence for Aggregate Science, School of Science and Engineering, Shenzhen Institute of Aggregate Science and Technology, The Chinese University of Hong Kong, Shenzhen (CUHK-Shenzhen), Shenzhen, China. tangbenz@cuhk.edu.cn.ORCID http://orcid.org/0000-0002-0293-964X
Hai-Tao FengShaanxi Key Laboratory of Phytochemistry, AIE Research Center, College of Chemistry and Chemical Engineering, Baoji University of Arts and Sciences, Baoji, China. haitaofeng907@163.com.ORCID http://orcid.org/0000-0003-2388-0955
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Malignant tumours frequently evade conventional therapies due to their complexity and high recurrence rates. To overcome these limitations, an integrated theranostic nanoplatform was developed through modification of a NIR-II emitting aggregation-induced emission photosensitizer with folic acid and the polydentate ligand (DOTA), followed by radiolabeling with
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Integrated theranostic nanoplatform empowers precision cancer care via radionuclide-labeled NIR-II aggregation-induced emission luminogens. · full record | OpenQuestion